Sun Pharma drops plan to merge Taro with itself: Report

Subscribe to GoodReturns
For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

    Mumbai based Sun Pharmaceutical has finally dropped the idea of merging Israeli drug unit Taro with itself following some conflicts over profit sharing with some minority shareholders of the NYSE listed firm.

    The decision to terminate the merger agreement was taken on Friday. The two companies had decided in last August to merge as Sun already held 66.5 per cent stake in Taro.

    Sun, which had signed the deal to buy Taro for USD 454 million in May 2007, was facing disagreement from at least two shareholders of Taro — Raging Capital and Grand Slam — who raised objections on the deal value.

    Sun Pharma also tried to woo the minority shareholders of Taro by offering cash payment of USD 39.50, upon the close of the merger deal in exchange for a Taro share.

    However, the offer didn't yield any result as Taro's shares are now traded at USD 50.5 on the NYSE, about 28 per cent higher than Sun's current offer of USD 39.5.

    Read more about: sun pharma
    Company Search
    Enter the first few characters of the company's name or the NSE symbol or BSE code and click 'Go'
    India's LARGEST EVER political poll. Have you participated yet?

    Find IFSC

    We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more